A 32-year-old woman, previously diagnosed with schizophrenia and undergoing long-term treatment with clozapine, experienced the onset of symptoms such as shallow coma, persistent high fever, and increased muscle tone one day after transitioning from clozapine to amisulpride. Combining with elevated creatine kinase levels and other examination findings, the patient was diagnosed with amisulpride-related neuroleptic malignant syndrome (NMS). Amisulpride treatment was promptly discontinued, and the patient was treated with bromocriptine, but it failed to relieve the symptoms. On the same day, intravenous administration of dantrolene sodium was conducted, then her body temperature decreased, convulsions and tremors improved, and other symptoms gradually relieved. After 5 days, her consciousness improved, and she was discharged after 10 days. Amisulpride-related NMS are relatively rare, and dantrolene sodium can be used as a potential option when conventional treatments prove ineffective.

1.薛莹, 司方莹, 刘帅兵. 1例抗精神病药恶性综合征患者的药学监护及文献复习[J]. 中国药房, 2020, 31(2): 234-238. [Xue Y, Si FY, Liu SB. Pharmaceutical care of 1 case of neuroleptics-induced malignant syndrome andliterature review[J]. China Pharmacy, 2020, 31(2): 234-238.] DOI: 10.6039/j.issn.1001-0408.2020.02.20.

2.Sato I, Onishi H, Kawanishi C, et al. Neuroleptic malignant syndrome in patients with cancer: a systematic review[J]. BMJ Support Palliat Care, 2020, 10(3): 265-270. DOI: 10.1136/bmjspcare-2020-002200.

3.Kiyingi M, Bongomin F, Kizito M, et al. Neuroleptic malignant syndrome: early diagnosis saves lives in low-resource settings[J]. Int Med Case Rep J, 2020, 13: 359-362. DOI: 10.2147/IMCRJ.S270332.

4.Angulo NY, Castaño PA, Gómez CC, et al. Neuroleptic malignant syndrome associated with acute organophosphate poisoning: case report[J]. Biomedica, 2022, 42(3): 445-449. DOI: 10.7705/biomedica.6428.

5.Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome[J]. Am J Psychiatry, 1999, 156(2): 169-180. DOI: 10.1176/ajp.156.2.169.

6.Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome[J]. Am J Psychiatry, 2007, 164(6): 870-876. DOI: 10.1176/ajp.2007.164.6.870.

7.Nielsen RE, Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study[J]. Can J Psychiatry, 2012, 57(8): 512-518. DOI: 10.1177/070674371205700810.

8.何彦侠, 赵慧敏, 陈兴, 等. 恶性综合征临床误诊分析[J]. 临床误诊误治, 2020, 33(9): 20-23. [He YX, Zhao HM, Chen X, et al. Analysis of causes of clinical misdiagnosis in neuroleptic malignant syndrome[J]. Clinical Misdiagnosis & Mistherapy, 2020, 33(9): 20-23.] DOI: 10.3969/j.issn.1002-3429.2020.09.006.

9.Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy[J]. Arch Intern Med, 1989, 149(9): 1927-1931. DOI: 10.1001/archinte.149.9.1927.

10.Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction[J]. Acta Psychiatr Scand, 1986, 73(4): 337-347. DOI: 10.1111/j.1600-0447.1986.tb02694.x.

11.Sarkar S, Gupta N. Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association[J]. BJPsych Bulletin, 2017, 41(4): 211-216. DOI: 10.1192/pb.bp.116. 053736.

12.Raj K, Jajor TR, Khandelwal A, et al. Neuroleptic malignant syndrome with minimal dose of amisulpride[J]. J Acute Med, 2017, 7(3): 122-124. DOI: 10.6705/j.jacme. 2017.0703.005.

13.Yu H, Tan L, Zhu T, et al. A WeChat applet-based national remote emergency system for malignant hyperthermia in China: a usability study[J]. BMC Med Inform Decis Mak, 2023, 23(1): 175. DOI: 10.1186/s12911-023-02275-4.

14.梁英, 刘登堂, 司天梅, 等. 氨磺必利治疗精神分裂症临床应用专家意见[J]. 中国心理卫生杂志, 2017, 31(6): 425-431. [Liang Y, Liu DT, Si TM, et al. Expert advice on practical use of amisulpride in treatment of schizophrenia[J]. Chinese Mental Health Journal, 2017, 31(6): 425-431.] DOI: 10.3969 /j.issn.1000-6729. 2017.06.001.

15.Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency[J]. Acta Psychiatr Scand, 2017, 135(5): 398-408. DOI: 10. 1111/acps.12694.

16.Kuhlwilm L, Schönfeldt-lecuona C, Gahr M, et al. The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome(Review) [J]. Acta Psychiatr Scand, 2020, 142(3): 233-241. DOI: 10.1111/acps.13215.

17.American Psychiatric Association.Diagnostic and statistical manual of mental disorders, 5 th ed[M]. Washington, DC: American Psychiatric Association, 2013: 709-711.

18.Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method[J]. J Clin Psychiatry, 2011, 72(9): 1222-1228. DOI: 10.4088/JCP.10m06438.

19.Gurrera RJ, Mortillaro G, Velamoor V, et al. A validation study of the International Consensus Diagnostic Criteria for neuroleptic malignant syndrome[J]. J Clin Psychopharmacol, 2017, 37(1): 67-71. DOI: 10.1097/JCP. 0000000000000640.

20.Schönfeldt-lecuona C, Kuhlwilm L, Cronemeyer M, et al. Treatment of the neuroleptic malignant syndrome in international therapy guidelines: a comparative analysis[J]. Pharmacopsychiatry, 2020, 53(2): 51-59. DOI: 10.1055/a-1046-1044.

21.Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome[J]. J Am Acad Child Adolesc Psychiatry, 1992, 31(6): 1161-1164. DOI: 10.1097/ 00004583-199211000-00028.

22.Levenson JN. Neuroleptic malignant syndrome[J]. Am J Psychiatry, 1985, 142(10): 1137-1145. DOI: 10.1176/ajp. 142.10.1137.

23.Assion HJ, Heinemann F, Laux G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review[J]. Eur Arch Psychiatry Clin Neurosci, 1998, 248(5): 231-239. DOI: 10.1007/s004060050043.

24.李英亭, 李思媛, 张炜. 抗精神病药物所致恶性综合征15例临床分析[J]. 临床医药文献电子杂志, 2017, 4(12): 2184-2186. [Li YT, Li SY, Zhang W. Clinical analysis of 15 cases of malignant syndrome caused by antipsychotic drugs[J]. Journal of Clinical Medical, 2017, 4(12): 2184-2186.] DOI: 10.3877/j.issn.2095-8242.2017. 12.003.